FDA approves belzutifan-lenvatinib combination for advanced renal cell carcinoma with a clear cell component

MRK•2026-09-24

The FDA approved belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component; the recommended daily doses are 120 mg of belzutifan and 20 mg of lenvatinib until disease progression or unacceptable toxicity.

FDA approves belzutifan-lenvatinib combination for advanced renal cell carcinoma with a clear cell component

1. FDA approval

Related News

Trump-Xi summit in Washington begins with great fanfare but low expectations

Brazilian court suspends new transfers from Braskem to Mexico's Idesa

Associated Bank hires Kelly Mould as managing director of Trust and Advisory Services

Microsoft to deliver Majorana-2 quantum technology to DARPA for on-site testing

US Federal Reserve proposes new stablecoin rules